Additive effect of factor X on the structure and stability of activated factor VII-induced fibrin clot in hemophilic plasma with inhibitor

Replacing deficient factor (F) VIII or FIX is the most common treatment strategy for congenital hemophilia; however, repeated infusions can promote the formation of FVIII or FIX inhibitors. Importantly, the appearance of these inhibitors significantly reduces the hemostatic effect of regular FVIII or FIX replacement [1]. Recombinant activated FVII (rFVIIa) and activated prothrombin complex concentrates (APCC) are used for hemostatic management in patients having hemophilia with inhibitors (PHwI).